[en] Aims The study aim was to assess the time-related risk of developing diabetic nephropathy [albumin excretion rate (AER) greater than or equal to 40 mg/24 h] from baseline covariates in Type 1 diabetic patients with either good or poor metabolic control (MC). Methods Based on material from the Diabetes Control and Complications Trial study (n = 1441), patients were considered as under good or poor MC if their HbA(1c) mean level up to last visit fell in the lowest (less than or equal to 6.9%) or highest (greater than or equal to 9.5%) quintile of the overall HbA(1c) distribution, respectively. Prevalence cases of nephropathy were excluded from the study. Survival analysis and Cox regression were applied to the data. Results Among patients with good MC (n = 277), 15% had developed nephropathy at the end of the study. Conversely, among patients with poor MC (n = 268), the proportion without the complication was 52%. When adjusting for MC, time to diabetic nephropathy was related to age (P < 0.0001), AER (P < 0.001), duration of diabetes (P < 0.005), body mass index (BMI) (P < 0.005), all at baseline, and to gender (P < 0.01). Patients with upper normal range AER levels, longer duration of diabetes and lower BMI were at higher risk, regardless of MC. The adverse effect of younger age on diabetic nephropathy was more marked in good than in poor MC. Although women tended to develop the complication more often under good MC, they appeared to be better protected under poor MC. Conclusions This study confirms occurrence of diabetic nephropathy under good MC and non-occurrence of the complication despite poor MC. It also demonstrates that some baseline covariates can affect, in a differential manner, time to diabetic nephropathy depending on MC.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Zhang, Liying
Krzentowski, Georges
Albert, Adelin ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Lefèbvre, Pierre ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Language :
English
Title :
Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control
Publication date :
July 2003
Journal title :
Diabetic Medicine: A Journal of the British Diabetic Association
Selby JV, Fitzsimmons SC, Newman JM, Katz PP, Sepe S, Showstack J. The natural history and epidemiology of diabetic nephropathy. Implications for prevention and control. JAMA 1990; 263: 1954-1960.
Thomas SM, Viberti GC. Is it possible to predict diabetic kidney disease? J Endocrinol Invest 2000; 23: 44-53.
Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985; 78: 785-794.
Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Eng J Med 1994; 330: 15-18.
The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
The DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
The DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
Turner R, Cull C, Holman R, for the UKPDS Group. A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-145.
The UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
The UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
Zhang L, Krzentowski G, Albert A, Lefèbvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001; 24: 1275-1279.
The DCCT Research Group. Design and methodologic considerations for the feasibility phase. Diabetes 1986; 35: 530-545.
The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-1720.
Molitch ME, Steffes MW, Cleary PA, Nathan DM, prepared by the DCCT Research group. Baseline analysis of renal function in the Diabetes Control and Complications Trial. Kidney Int 1993; 43: 668-674.
Harris EK, Albert A. Survivorship Analysis for Clinical Studies, 1st edn. New York: Marcel Dekker, 1991; 4: 77-125.
Akaike H. Use of an Information Theoretic Quantity for Statistical Model Identification. Proceedings of the Fifth Hawaii International Conference on System Sciences. North Hollywood, CA: Western Periodicals, 1972: 249-250.
Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol 1982; 100: 550-555.
Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-1432.
Royal College of Physicians of Edinburgh Diabetes Register Group. Near-normal urinary albumin concentrations predict progression to diabetic nephropathy in type 1 diabetes mellitus. Diabet Med 2000; 17: 782-791.
Schultz CJ, Neil HAW, Dalton RN, Dunger DB, on behalf of the Oxford Regional Prospective Study Group. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care 2000; 23: 1811-1815.
Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 590-596.
Microalbuminuria Collaborative Study Group. Microalbuminuria in type 1 diabetic patients. Prevalence and clinical characteristics. Diabetes Care 1992; 15: 495-501.
Mattock MB, Cronin N, Cavallo-Perin P, Idzior-Walus B, Penno G, Bandinelli S et al. Plasma lipids and urinary albumin excretion rate in type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med 2001; 18: 59-67.
Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T. Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes 1987; 36: 205-209.
Twyman S, Rowe D, Mansell P, Schapira D, Betts P, Leatherdale B. Longitudinal study of urinary albumin excretion in young diabetic patients - Wessex Diabetic Nephropathy Project. Diabet Med 2001; 18: 402-408.
Wiseman M, Viberti G, Mackintosh D, Jarrett RJ, Keen H. Glycaemia, arterial pressure and microalbuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1984; 26: 401-405.
Ritz E, Ogata H, Orth SR. Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab 2000; 26: 54-63.
Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
